MR1 and COVID-19: In a subset of our COVID-19 patient samples (n = 38), we were able to confirm that 80 % (median, range 36–93 %, Supplementary Fig. 1C) of the CD3+CD8+CD161+Vα7.2+ cells were also positive for the MR1-tetramer.